TY  - JOUR
AU  - Felton, Jessica
AU  - Raufman, Jean-Pierre
PY  - 2016
TI  - Is the ColDx assay a valid prognostic marker for stage II colon cancer?
JF  - Translational Cancer Research; Vol 5, Supplement 6 (November 30, 2016): Translational Cancer Research
Y2  - 2016
KW  - 
N2  - In the United States, colorectal cancer is the fourth most prevalent neoplasm and the second most frequent cause of cancer-related death (1). Surgery alone is standard-of-care for stage I cancer, whereas adjuvant chemotherapy is recommended for stage III. Surprisingly, despite its prevalence, the most appropriate management for stage II colon cancer remains uncertain. Currently-accepted guidelines recommend adjuvant chemotherapy for those considered ‘high-risk’ for recurrence, defined as stage T4 cancer, poorly-differentiated histology, inadequate lymph node sampling, positive or unknown margins, lympho-vascular or perineural invasion, bowel obstruction, or perforation (2).
UR  - https://tcr.amegroups.org/article/view/10753